Bipolar Disorder (Manic Depression) – Pipeline Insight, 2018

SKU: DPI38 | Last Updated On: 2019-04-09 | No. of Pages: 210 | Available Formats

Bipolar Disorder Pipeline Analysis

  • The “Bipolar Disorder (Manic Depression) – Pipeline Insights 2018″ report covers an in-depth analysis of bipolar disorder drug molecules currently undergoing clinical studies.
  • It provides a deep understanding of potential bipolar disorder drug molecules across all drug development phases. The report assesses the pipeline bipolar disorder molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, intranasal and others).
  • The report provides a snapshot of discontinued and dormant drugs too. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
  • The report covers company profiles key players in developing bipolar disorder drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.

 

The scope of the report

• Provides comprehensive understanding of active bipolar disorder pipeline drug candidates
• Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
• Provides a comparative analysis of key marketed products and pipeline drug candidates
• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
• Provides key info on players involved in clinical R&D of bipolar disorder drug candidates.
• Provides in-depth coverage of key news related to bipolar disorder drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

 

Why should I purchase this report

• To obtain an understanding of the current bipolar disorder pipeline landscape.
• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
• To valuably optimize R&D activities in-line with robust therapeutic drug markets.
• To devise strategic initiatives by identifying prospective partners with progressing projects.

Bipolar Disorder Pipeline Analysis

  • Bipolar disorder, also known as manic-depression, is a mental illness that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in usual activities, sleep problems, etc.
  • These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance.
  • People with bipolar disorder are also at higher risk of other diseases like thyroid disease, heart disease, diabetes, obesity, migraine headaches, and other physical illnesses.
  • There is a range of treatments to control the disorder. As bipolar disorder is a lifelong and recurrent illness, people with the disease need prolonged treatment to maintain or control of bipolar symptoms. A potential maintenance treatment plan includes medication and psychotherapy.
  • Medications such as valproic acid, lithium, and anticonvulsants are used to stabilize moods. Antidepressant medicines. Alternative treatments include Electroconvulsive Therapy (ECT) and herbal supplements.
  • To pipeline of bipolar disorders includes a varied range of products, some of them are like Cyclurad – a combination of cycloserine/lurasidone of NeuroRx is in the Phase 3 stage of development. Sep-22 of Sumitomo Dannippon is in phase 2 whereas SEP-378608 of the same company is being developed in Phase 1 clinical trial. Prodrugs of the already existing marketed prodrugs have gained value, and products like KP303 (prodrug of quetiapine XR) is in the preclinical stage of development.
  • Vraylar, an oral, once-daily atypical antipsychotic, was discovered and co-developed by Gedeon Richter and is licensed by Allergan in the US and Canada. For more than a decade both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine. Collaborated developments help to overcome the challenges of high costs.
  • The growing need to curb the financial burden of bipolar disorder drives the growth prospects for the global bipolar disorder therapeutics market.
  • It provides a comprehensive understanding of the emerging Phase III therapies for Bipolar Disorder (Manic Depression), which can turn out to be future, encouraging competitors for the marketed products. The complexity of bipolar disorder is yet to be answered.
  • Demographics is expected to drive the growth of total prevalence in the forecasted period for bipolar I disorder and bipolar II disorder. Some of the significant factors responsible for the market’s growth are the high incidence of bipolar disorder symptoms in the US, the rising awareness about these disorders, the growing number of pipeline products, and the increasing prevalence of pediatric bipolar disorders.
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest